Last reviewed · How we verify
Iopofosine I 131 single dose
Iopofosine I 131 is a phospholipid-drug conjugate that selectively targets and accumulates in cancer cells, allowing for targeted radiation therapy.
Iopofosine I 131 is a phospholipid-drug conjugate that selectively targets and accumulates in cancer cells, allowing for targeted radiation therapy. Used for Relapsed or refractory peripheral T-cell lymphoma.
At a glance
| Generic name | Iopofosine I 131 single dose |
|---|---|
| Also known as | I-131-CLR1404, CLR 131 |
| Sponsor | Cellectar Biosciences, Inc. |
| Drug class | Phospholipid-drug conjugate |
| Target | Phospholipid receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Iopofosine I 131 is a targeted alpha-particle therapy that utilizes a phospholipid-drug conjugate to selectively accumulate in cancer cells, where it emits alpha particles to induce cell death. This approach allows for a high dose of radiation to be delivered directly to the tumor site while minimizing exposure to surrounding healthy tissues.
Approved indications
- Relapsed or refractory peripheral T-cell lymphoma
Common side effects
- Fatigue
- Nausea
- Vomiting
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Iopofosine I 131 single dose CI brief — competitive landscape report
- Iopofosine I 131 single dose updates RSS · CI watch RSS
- Cellectar Biosciences, Inc. portfolio CI